抗抑郁药使用与不良健康结局关联的系统性伞状综述
仅儿童青少年自杀尝试或完成、产前及孕期暴露与自闭症谱系障碍、早产和低Apgar评分显示令人信服的证据,但经混杂校正后均不再成立。多数抗抑郁药不良结局缺乏令人信服的证据支持。
要点
- 仅少数关联达令人信服证据,经指征混杂校正后无一保留。
- 多数抗抑郁药不良健康结局未获令人信服证据支持。
- 该伞状综述未发现抗抑郁药的绝对禁忌证。
核心结论
- 多数与抗抑郁药使用相关的推定不良健康结局可能缺乏令人信服的证据支持。
- 指征混杂可能改变少数具有令人信服证据的关联。
- 抗抑郁药用于治疗精神障碍似乎是安全的,该伞状综述未发现绝对禁忌证。
研究设计与样本
- 检索PubMed、Scopus和PsycINFO自建库至2019年4月5日,仅纳入队列或病例对照设计的观察性研究荟萃分析。
- 由两名独立评审者记录数据并评估方法学质量,证据等级按既定标准排序。
- 采用随机效应模型,证据等级分为令人信服、高度提示、提示、弱或无显著性。
主要发现
- 52个关联(43.4%)存在大异质性(I²>50%)。
- 17个关联(14.2%)存在小样本效应,9个关联(7.5%)存在超额显著性偏倚。
- 主分析和敏感性分析均显示令人信服证据的关联包括:儿童青少年抗抑郁药使用与自杀尝试或完成风险、产前及孕期抗抑郁药暴露与自闭症谱系障碍、早产和低Apgar评分。
- 上述关联在调整指征混杂的敏感性分析后均不再保留令人信服证据。
关键数值与推荐
- 证据等级标准:令人信服、高度提示、提示、弱或无显著性。
- 大异质性定义为I²>50%。
临床怎么用
- 临床应认识到多数抗抑郁药不良结局关联缺乏令人信服证据,抗抑郁药治疗精神障碍似乎安全。
- 对儿童青少年自杀风险、孕期暴露与自闭症谱系障碍、早产和低Apgar评分等关联需谨慎解读,因指征混杂可能影响结果。
- 需更多匹配基础疾病的研究以明确指征混杂程度和其他偏倚。
局限性
- 仅纳入观察性研究的荟萃分析,可能存在指征混杂等偏倚。
- 部分关联存在大异质性、小样本效应和超额显著性偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Antidepressant use is increasing worldwide. Yet, contrasting evidence on the safety of antidepressants is available from meta-analyses, and the credibility of these findings has not been quantified. OBJECTIVE: To grade the evidence from published meta-analyses of observational studies that assessed the association between antidepressant use or exposure and adverse health outcomes. DATA SOURCES: PubMed, Scopus, and PsycINFO were searched from database inception to April 5, 2019. EVIDENCE REVIEW: Only meta-analyses of observational studies with a cohort or case-control study design were eligible. Two independent reviewers recorded the data and assessed the methodological quality of the included meta-analyses. Evidence of association was ranked according to established criteria as follows: convincing, highly suggestive, suggestive, weak, or not significant. RESULTS: Forty-five meta-analyses (17.9%) from 4471 studies identified and 252 full-text articles scrutinized were selected that described 120 associations, including data from 1012 individual effect size estimates. Seventy-four (61.7%) of the 120 associations were nominally statistically significant at P ≤ .05 using random-effects models. Fifty-two associations (43.4%) had large heterogeneity (I2 > 50%), whereas small-study effects were found for 17 associations (14.2%) and excess significance bias was found for 9 associations (7.5%). Convincing evidence emerged from both main and sensitivity analyses for the association between antidepressant use and risk of suicide attempt or completion among children and adolescents, autism spectrum disorders with antidepressant exposure before and during pregnancy, preterm birth, and low Apgar scores. None of these associations remained supported by convincing evidence after sensitivity analysis, which adjusted for confounding by indication. CONCLUSIONS AND RELEVANCE: This study's findings suggest that most putative adverse health outcomes associated with antidepressant use may not be supported by convincing evidence, and confounding by indication may alter the few associations with convincing evidence. Antidepressant use appears to be safe for the treatment of psychiatric disorders, but more studies matching for underlying disease are needed to clarify the degree of confounding by indication and other biases. No absolute contraindication to antidepressants emerged from this umbrella review.
引用
- Dragioti E, Solmi M, Favaro A, et al. Association of Antidepressant Use With Adverse Health Outcomes: A Systematic Umbrella Review. JAMA Psychiatry. 2019. PMID: 31577342. doi:10.1001/jamapsychiatry.2019.2859
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。